Edgemond James's Form 4 filing
United Therapeutics Corp (UTHR) · filed Oct 1, 2024
- Accession no.
- 0001415889-24-024191
- Filed
- Oct 1, 2024
- Trade date
- Sep 30, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 8 non-derivative transactions and 4 derivative transactions. Open-market sales total $2.79M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Edgemond JamesCIK 0001636178 | Officer (CFO AND TREASURER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 30, 2024 | Common Stock | MOption exerciseAcquired | +3,267 | $120.26 | +$392,889.42 | 8,069 | Direct | |
| Sep 30, 2024 | Common Stock | SSaleDisposed | −3,267 | $358.62 | −$1,171,611.54 | 4,802 | Direct | |
| Sep 30, 2024 | Common Stock | MOption exerciseAcquired | +3,400 | $117.76 | +$400,384 | 8,202 | Direct | |
| Sep 30, 2024 | Common Stock | SSaleDisposed | −3,400 | $358.62 | −$1,219,308 | 4,802 | Direct | |
| Sep 30, 2024 | Common Stock | MOption exerciseAcquired | +817 | $120.26 | +$98,252.42 | 5,619 | Direct | |
| Sep 30, 2024 | Common Stock | SSaleDisposed | −553 | $358.62 | −$198,316.86 | 5,066 | Direct | |
| Sep 30, 2024 | Common Stock | MOption exerciseAcquired | +850 | $117.76 | +$100,096 | 5,916 | Direct | |
| Sep 30, 2024 | Common Stock | SSaleDisposed | −572 | $358.62 | −$205,130.64 | 5,344 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 30, 2024 | Common Stock | MOption exerciseDisposed | −3,267 | $0.00 | $0 | 21,237 | Direct | |
| Sep 30, 2024 | Common Stock | MOption exerciseDisposed | −3,400 | $0.00 | $0 | 133,600 | Direct | |
| Sep 30, 2024 | Common Stock | MOption exerciseDisposed | −817 | $0.00 | $0 | 20,420 | Direct | |
| Sep 30, 2024 | Common Stock | MOption exerciseDisposed | −850 | $0.00 | $0 | 132,750 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.